Weekly Topotecan Therapy in Patients With Ovarian Cancer

Phase 2TerminatedNCT00194935

Weill Medical College of Cornell University32 enrolled

Overview

The purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.

Patients with Stage IIIC and IV optimally-debulked ovarian cancer will be treated with 6 cycles (every 3 weeks) of carboplatin (AUC 5) and paclitaxel (175 mg/m2). Patients who demonstrate a complete clinical response to this regimen will then be treated with topotecan consolidation (4 mg/m2 weekly x 8 weeks for one cycle followed by a break in the 9th week) for a maximum of 3 cycles. Primary endpoints will be toxicity and the determination of the appropriate dose, schedule, and duration of topotecan for further consolidation trials.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Ovarian Cancer

Interventions

TopotecanDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have a histopathologic diagnosis of epithelial ovarian cancer. * Patients must have completed front-line chemotherapy and be clinically NED (CA 125 \<35, negative CT scan, negative physical exam). * Patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative). * Patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy. * Topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy. * Patients may have had only one prior chemotherapy regimen. Exclusion Criteria: * Patients with a concomitant malignancy other than squamous cell or basal cell skin cancer. * Patients who are pregnant or breast-feeding.

Locations (1)

Weill Medcial College of Cornell University

New York, New York, United States

Outcomes

Primary Outcomes

The objective of this study is to evaluate the safety and feasibility of weekly topotecan consolidation therapy in patients with epithelial ovarian cancer.

Secondary Outcomes

To determine the efficacy (Progression free survival) of weekly topotecan as consolidation therapy in ovarian cancer patients who are clinically NED or have microscopic disease only after first-line chemotherapy.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.